RANBAXY CONTINUES TO IMPROVE PERFORMANCE ACROSS DEVELOPED AND EMERGING MARKETS

Printer-friendly versionPDF version

Sales $474 Mn, EBITDA $95 Mn, PAT $67 Mn

Gurgaon, India, May 10, 2011

The Board of Directors of Ranbaxy Laboratories Limited (RLL), at their meeting held today, took on record the unaudited results for the quarter ended March 31, 2011.

Key Financial Highlights

Financial Performance for the quarter ended March 31, 2011 (Q1’11)

Ranbaxy’s base business Sales, EBITDA and PAT continued to improve and were higher than the corresponding quarter. Revenue and profitability numbers for Q1, 2010 and 2011 are not strictly comparable, because of the varying FTF contributions to the overall results.

Commenting on the business results for the quarter, Mr. Arun Sawhney, Managing Director, Ranbaxy, said, “We have started the year on a positive note and I am pleased with the sustained performance of key geographies as they continued to deliver superior sales. Leadership initiatives such as Viraat, in India, and a change in business models in some geographies, have also provided further impetus.”

Key Highlights/Developments

Global Sales

Consolidated sales for the quarter were $474 Mn (Rs. 21,468 Mn) as compared to $541 Mn (Rs. 24,847 Mn) in the corresponding quarter, previous year. Emerging markets contributed $237 Mn in sales, a growth of 12%. Developed markets recorded sales of $212 Mn. 

News Source : RANBAXY CONTINUES TO IMPROVE PERFORMANCE ACROSS DEVELOPED AND EMERGING MARKETS